Jennifer Garner’s Once Upon a Farm Revives IPO Plans Amid Market Optimism
Once Upon a Farm, the organic food company co-founded by actress Jennifer Garner, has announced the resumption of its initial public offering (IPO) plans. The company, renowned for its range of baby food and children’s snacks, had previously postponed its IPO due to a government shutdown. However, a recent filing with the Securities and Exchange Commission (SEC) indicates a renewed commitment to going public.
The updated S-1 filing, submitted on January 28, 2026, proposes a share price range of $17 to $19. This move suggests a positive shift in the IPO market, potentially signaling a broader recovery. According to IPOScoop, Once Upon a Farm is slated to debut on the stock market on February 6.
Founded in 2015 by entrepreneurs Cassandra Curtis and Ari Raz, Once Upon a Farm welcomed Jennifer Garner as a co-founder in 2017. Garner’s involvement has been instrumental in elevating the brand’s profile and expanding its reach. The company’s mission is to provide nutritious, organic food options for children, emphasizing freshness and quality.
To date, Once Upon a Farm has secured nearly $100 million in funding from investors such as S2G Ventures and CAVU Consumer Partners. The upcoming IPO aims to raise at least $208.9 million, positioning the company’s valuation at approximately $764.4 million. Leading financial institutions Goldman Sachs and J.P. Morgan are serving as the primary underwriters for this offering.
The decision to proceed with the IPO reflects a strategic move to capitalize on favorable market conditions and investor interest in health-conscious consumer products. Once Upon a Farm’s commitment to organic, high-quality ingredients has resonated with a growing demographic of health-aware parents seeking better nutrition for their children.
As the IPO date approaches, industry observers are keenly watching to see how Once Upon a Farm’s public debut will influence the organic food sector and the broader IPO landscape. The company’s performance could serve as a bellwether for other health-focused startups considering public offerings in the near future.
